Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-25-005075
Filing Date
2025-07-14
Accepted
2025-07-14 09:18:08
Documents
37
Period of Report
2025-05-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q cnbx_i10q-53125.htm   iXBRL 10-Q 378708
2 CERTIFICATION cnbx_ex3101.htm EX-31.1 10224
3 CERTIFICATION cnbx_ex3102.htm EX-31.2 10458
4 CERTIFICATION cnbx_ex3201.htm EX-32.1 5153
5 CERTIFICATION cnbx_ex3202.htm EX-32.2 4841
  Complete submission text file 0001683168-25-005075.txt   1962103

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnbx-20250531.xsd EX-101.SCH 14880
7 XBRL CALCULATION FILE cnbx-20250531_cal.xml EX-101.CAL 23925
8 XBRL DEFINITION FILE cnbx-20250531_def.xml EX-101.DEF 35157
9 XBRL LABEL FILE cnbx-20250531_lab.xml EX-101.LAB 173105
10 XBRL PRESENTATION FILE cnbx-20250531_pre.xml EX-101.PRE 133575
39 EXTRACTED XBRL INSTANCE DOCUMENT cnbx_i10q-53125_htm.xml XML 166855
Mailing Address #3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814
Business Address #3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814 877-424-2429
CNBX Pharmaceuticals Inc. (Filer) CIK: 0001343009 (see all company filings)

EIN.: 203373669 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 000-52403 | Film No.: 251120279
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)